Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ending June 30, 2020 and provided an operating forecast and program updates. Ligand man
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ending June 30, 2020 and provided an
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.COVID-19 news flow continued to pour in, with big pharma tie-ups f
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in,...
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 30) Achieve Life Sciences Inc (NASDAQ: ACHV) Annexon Inc (NASDAQ: ANNX) (IPOed July 24) Atossa Therapeutics...
Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, and Cyclica, whose AI-augmented, in
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 23) Abbott Laboratories (NYSE: ABT) ABIOMED, Inc. (NASDAQ: ABMD) Acceleron Pharma Inc (NASDAQ: XLRN) Aerpio...
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) ABIOMED, Inc. (NASDAQ: ABMD) Assembly Biosciences Inc (NASDAQ: ASMB) Bio-Rad Laboratories, Inc. (NYSE: BIO)...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report second quarter 2020 financial results on August 3, 2020. Ligand’s CEO John Higgins, President and COO
Ligand Pharmaceuticals (NASDAQ:LGND) had its target price upped by Benchmark from $135.00 to $155.00 in a research report issued on Tuesday, The Fly reports. The firm currently has a “buy” rating
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report second quarter 2020 financial results on August 3, 20
Ligand Pharmaceuticals Inc. (NASDAQ:LGND)’s share price traded up 5.2% during trading on Tuesday after Benchmark raised their price target on the stock from $135.00 to $155.00. Benchmark currently h
VICTORIA , July 13, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (IPA.V) (IPATF) (TQB2.F), a leader in full-service, therapeutic antibody discovery and development, today ann
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
The multicenter Phase 2 trial, Sermonix’s Evaluation of Lasofoxifene and Abemaciclib in ESR1 Mutations, is projected to begin enrollment in Q3 2020. COLUMBUS, Ohio, July 08, 2020 (GLOBE NEWSWIRE)
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE